Silencing of zinc finger protein 703 inhibits medullary thyroid carcinoma cell proliferation in vitro and in vivo

Yang,Xiaolin; Liu,Geling; Li,Weijuan; Zang,Luyang; Li,Ding; Wang,Qianqian; Yu,Fang; Xiang,Xiuxiu

doi:10.3892/ol.2019.11153

Silencing of zinc finger protein 703 inhibits medullary thyroid carcinoma cell proliferation in vitro and in vivo

Authors:
- Xiaolin Yang
- Geling Liu
- Weijuan Li
- Luyang Zang
- Ding Li
- Qianqian Wang
- Fang Yu
- Xiuxiu Xiang
View Affiliations

Affiliations: Department of Endocrinology (Section I), Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China
Published online on: November 28, 2019 https://doi.org/10.3892/ol.2019.11153
Pages: 943-951
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zinc finger protein 703 (ZNF703) is a new member of the zinc finger protein family of transcription factors that plays an important role during embryogenesis in metazoans. The overexpression of ZNF703 contributes to tumorigenesis and progression of a number of malignancies by activating the Akt/mammalian target of rapamycin (mTOR) signaling pathway. This pathway is activated in medullary thyroid cancer (MTC), but its mechanism of action is not yet fully understood. The aim of the present study was to examine the role of ZNF703 and its association with Akt/mTOR activation in MTC. The present study used the phosphorylation of Akt1 protein at serine 473 (pAkt473) as an indicator of signaling activation. Immunohistochemistry (IHC) staining and western blot analyses were performed in order to examine the expression of ZNF703 in 34 cases of MTC and 12 cases of corresponding normal thyroid tissues. ZNF703 expression in MTC was significantly higher compared with the corresponding normal thyroid tissues (P<0.05). Furthermore, expression of ZNF703 was associated with tumor size, lymph node metastasis and advanced stage of disease. IHC also demonstrated that the level of ZNF703 was positively correlated with p‑Akt473 in the 34 cases of MTC. The human MTC cell line TT was selected for further investigation as TT cells exhibit Akt/mTOR activation. The biological effects of silencing ZNF703 in TT cells on proliferation and apoptosis, both in vitro and in vivo were investigated in the present study. ZNF703 silencing inhibited the proliferation of TT cells in vitro and inhibited xenograft tumor growth in vivo. These effects were accompanied by the substantial decrease of pAkt473 and the induction of p53 protein. These results demonstrate that ZNF703 may play a relevant role in MTC due to its association with the Akt/mTOR signaling pathway.

View Figures

View References

1	Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
2	Kim J, Gosnell JE and Roman SA: Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. Oct 15–2019.(Epub ahead of print). PubMed/NCBI
3	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
4	Sherman SI: Thyroid carcinoma. Lancet. 361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
5	Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A and D'Armiento M: Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid. 16:1151–1155. 2006. View Article : Google Scholar : PubMed/NCBI
6	Matias-Guiu X and De Lellis R: Medullary thyroid carcinoma: A 25-year perspective. Endocr Pathol. 25:21–29. 2014. View Article : Google Scholar : PubMed/NCBI
7	Rahmani N, Abbas Hashemi S, Fazli M and Raisian M: Clinical management and outcomes of papillary, follicular and medullary thyroid cancer, surgery. Med Glas (Zenica). 10:164–167. 2013.PubMed/NCBI
8	Maxwell JE, Sherman SK, O'Dorisio TM and Howe JR: Medical management of metastatic medullary thyroid cancer. Cancer. 120:3287–3301. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ernani V, Kumar M, Chen AY and Owonikoko TK: Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treat Rev. 50:89–98. 2016. View Article : Google Scholar : PubMed/NCBI
10	Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al: Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 25:567–610. 2015. View Article : Google Scholar : PubMed/NCBI
11	Hu Q, Lin X, Ding L, Zeng Y, Pang D, Ouyang N, Xiang Y and Yao H: ARHGAP42 promotes cell migration and invasion involving PI3K/Akt signaling pathway in nasopharyngeal carcinoma. Cancer Med. 7:3862–3874. 2018. View Article : Google Scholar : PubMed/NCBI
12	Gagliano T, Bellio M, Gentilin E, Molè D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, et al: mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr Relat Cancer. 20:463–475. 2013. View Article : Google Scholar : PubMed/NCBI
13	Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF, Wells SA Jr and Santoro M: Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res. 18:3532–3540. 2012. View Article : Google Scholar : PubMed/NCBI
14	Campos M, Kool MM, Daminet S, Ducatelle R, Rutteman G, Kooistra HS, Galac S and Mol JA: Upregulation of the PI3K/Akt pathway in the tumorigenesis of canine thyroid carcinoma. J Vet Intern Med. 28:1814–1823. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kouvaraki MA, Liakou C, Paraschi A, Dimas K, Patsouris E, Tseleni-Balafouta S, Rassidakis GZ and Moraitis D: Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery. 150:1258–1265. 2011. View Article : Google Scholar : PubMed/NCBI
16	Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L and Vitale G: PI3K/Akt/mTOR signaling in medullary thyroid cancer: A promising molecular target for cancer therapy. Endocrine. 48:363–370. 2015. View Article : Google Scholar : PubMed/NCBI
17	Giunti S, Antonelli A, Amorosi A and Santarpia L: Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol. 2013:8031712013. View Article : Google Scholar : PubMed/NCBI
18	Bikas A, Vachhani S, Jensen K, Vasko V and Burman KD: Targeted therapies in thyroid cancer: An extensive review of the literature. Expert Rev Clin Pharmacol. 9:1299–1313. 2016. View Article : Google Scholar : PubMed/NCBI
19	Burke JF, Schlosser L, Harrison AD, Kunnimalaiyaan M and Chen H: MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through akt inhibition. Ann Surg Oncol. 20:3862–3868. 2013. View Article : Google Scholar : PubMed/NCBI
20	Andreazzoli M, Broccoli V and Dawid IB: Cloning and expression of noz1, a zebrafish zinc finger gene related to Drosophila nocA. Mech Dev. 104:117–120. 2001. View Article : Google Scholar : PubMed/NCBI
21	Pereira-Castro I, Costa AM, Oliveira MJ, Barbosa I, Rocha AS, Azevedo L and da Costa LT: Characterization of human NLZ1/ZNF703 identifies conserved domains essential for proper subcellular localization and transcriptional repression. J Cell Biochem. 114:120–133. 2013. View Article : Google Scholar : PubMed/NCBI
22	Slorach EM, Chou J and Werb Z: Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Gene Dev. 25:471–484. 2011. View Article : Google Scholar : PubMed/NCBI
23	Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adélaïde J, Baudelet E, Esteyriès S, et al: ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med. 3:153–166. 2011. View Article : Google Scholar : PubMed/NCBI
24	Baykara O, Dalay N, Kaynak K and Buyru N: ZNF703 overexpression may act as an oncogene in non-small cell lung cancer. Cancer Med. 5:2873–2878. 2016. View Article : Google Scholar : PubMed/NCBI
25	Yang G, Ma F, Zhong M, Fang L, Peng Y, Xin X, Zhong J, Yuan F, Gu H, Zhu W and Zhang Y: ZNF703 acts as an oncogene that promotes progression in gastric cancer. Oncol Rep. 31:1877–1882. 2014. View Article : Google Scholar : PubMed/NCBI
26	Li K, Wang J, Han J, Lan Y, Xie C, Pan S and Liu L: Overexpression of ZNF703 facilitates tumorigenesis and predicts unfavorable prognosis in patients with cholangiocarcinoma. Oncotarget. 7:76108–76117. 2016.PubMed/NCBI
27	Wang H, Deng X, Zhang J, Ou Z, Mai J, Ding S and Huo S: Elevated expression of zinc finger protein 703 promotes cell proliferation and metastasis through PI3K/AKT/GSK-3β signalling in oral squamous cell carcinoma. Cell Physiol Biochem. 44:920–934. 2017. View Article : Google Scholar : PubMed/NCBI
28	Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M and Shen K: Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. PLoS One. 8:e720532013. View Article : Google Scholar : PubMed/NCBI
29	Metgud R, Astekar MS, Soni A, Naik S and Vanishree M: Conventional xylene and xylene-free methods for routine histopathological preparation of tissue sections. Biotech Histochem. 88:235–241. 2013. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Pereira F, Duarte-Pereira S, Silva RM, da Costa LT and Pereira-Castro I: Evolution of the NET (NocA, Nlz, Elbow, TLP-1) protein family in metazoans: Insights from expression data and phylogenetic analysis. Sci Rep. 6:383832016. View Article : Google Scholar : PubMed/NCBI
32	Wade M, Li YC and Wahl GM: MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96. 2013. View Article : Google Scholar : PubMed/NCBI
33	Thirunavukarasou A, Singh P, Govindarajalu G, Bandi V and Baluchamy S: E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation. Mol Cell Biochem. 390:93–100. 2014. View Article : Google Scholar : PubMed/NCBI
34	Chang H, Li C, Huo K, Wang Q, Lu L, Zhang Q, Wang Y and Wang W: Luteolin prevents H2O2-induced apoptosis in H9C2 cells through modulating Akt-P53/Mdm2 signaling pathway. Biomed Res Int. 2016:51258362016. View Article : Google Scholar : PubMed/NCBI
35	Zhu Y, Dai B, Zhang H, Shi G, Shen Y and Ye D: Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis. Cancer Lett. 380:369–374. 2016. View Article : Google Scholar : PubMed/NCBI
36	Tu Y, Kim E, Gao Y, Rankin GO, Li B and Chen YC: Theaflavin-3, 3′-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells. Int J Oncol. 48:2657–2665. 2016. View Article : Google Scholar : PubMed/NCBI
37	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI